Project Grant R34CA318298
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $310K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
East Lansing, MI 48824, USA
Similar Awards
- The National Cancer Institute awarded the University of Kentucky Research Foundation $610,625 on August 5, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to implement a pragmatic effectiveness trial of screening, brief intervention, and referral to treatment (SBIRT) for hazardous alcohol use among cancer survivors. The award funds a five-year study randomizing 1,200 head, neck, and esophageal cancer survivors to either a multilevel intervention called...
- The National Cancer Institute awarded The Ohio State University $647,762 on July 14, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to optimize social media messages targeting young adult women about breast cancer risk from alcohol consumption. The funded research combines self-report and psychophysiological measures to identify optimal features of co-created social media messages communicating breast cancer risk from alcohol consumption and determine whether persuasive effects...
- The National Cancer Institute awarded Regents of the University of Michigan $785,278 on August 14, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate the efficacy of the MI Sleep Coach App, a mobile cognitive behavioral therapy for insomnia (CBT-I) intervention designed specifically for cancer survivors. Sleep disturbances affect over 50 percent of breast, prostate, and colorectal cancer survivors and are associated with negative effects on physical and...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Michigan $682,272 under the Cancer Cause and Prevention Research program (CFDA 93.393) on September 1, 2025, for a two-year project (completion date August 31, 2027) to assess the feasibility and acceptability of a multifaceted electronic health record (EHR)-integrated mobile health intervention designed to reduce post-operative readmissions following radical cystectomy. The intervention consists of an...
- The National Cancer Institute awarded The Research Foundation For The State University of New York $467,581 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to support a mixed-methods ecological momentary assessment study examining substance use behaviors and underlying socioecological drivers among young adult cancer survivors in early survivorship. The research identifies mechanisms of substance use—including tobacco, alcohol, cannabis, illicit drugs, and...
- The National Institute on Drug Abuse awarded Michigan State University (doing business as Henry Ford Health+Michigan State University Health Sciences) $367,362 on March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and test a patient-engaged electronic screening and brief intervention (ESBI) combined with tailored text messaging to reduce cannabis use in pregnancy. The project will establish a patient advisor committee that partners with pregnant...
- The National Cancer Institute awarded New York University $310,185 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and feasibility-test a mobile application delivering an evidence-based intervention that addresses financial stress and smoking cessation. The recipient will develop a smartphone app version of the FIERCE (Financial Freedom from Cigarettes) intervention, which integrates financial coaching into smoking cessation treatment. The work...
- The National Cancer Institute awarded Washington State University $560,858 on July 21, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial evaluating a remote telehealth intervention combining varenicline and app-based contingency management for rural smokers with alcohol use disorder. The trial will enroll 192 rural smokers seeking smoking cessation treatment and living with an alcohol use disorder. Participants will be...
- The National Cancer Institute awarded the Regents of the University of Michigan $646,881 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop small-molecule inhibitors of ASH1L, a histone methyltransferase, as a therapeutic strategy for acute leukemia. The funded research targets acute myeloid leukemia (AML), which carries a five-year survival rate of approximately 27% with current treatments. The work focuses on blocking expression of HOX genes—particularly...
- The National Cancer Institute awarded Wayne State University $398,544 on August 14, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to build and test a clinic-based sleep care pathway for oncology patients with sleep disorders. The project, titled ONC-SLEEP COLLABORATIVE: COMISA COLLABORATIVE CARE INTEGRATION IN ONCOLOGY, addresses comorbid insomnia and obstructive sleep apnea (COMISA) in cancer patients through a team-based collaborative care model. Aim 1...